FGFR1 amplification is frequent in Sq-NSCLC (4.6–22%, Table 1) and in breast cancer (5–15%), but is less common in other cancer types such as ovarian (5%) and colorectal (2%) carcinomas (4, 18, 22, 42) (Supplemental Table S2). Here, FGFR1 is linked to non-small cell lung carcinoma.